Movatterモバイル変換

[0]ホーム
URL:

Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Nature Machine Intelligence
  • Comment
  • Published:

Dual use of artificial-intelligence-powered drug discovery

Nature Machine Intelligencevolume 4, pages189–191 (2022)Cite this article

Subjects

An international security conference explored how artificial intelligence (AI) technologies for drug discovery could be misused for de novo design of biochemical weapons. A thought experiment evolved into a computational proof.

This is a preview of subscription content,access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

9,800 Yen / 30 days

cancel any time

Subscribe to this journal

Receive 12 digital issues and online access to articles

￥14,900 per year

only ￥1,242 per issue

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

￥ 4,980

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: At-SNE plot visualization of the LD50 dataset and top 2,000 MegaSyn AI-generated and predicted toxic molecules illustrating VX.

References

  1. Spiez Convergence Conferencehttps://www.spiezlab.admin.ch/en/home/meta/refconvergence.html (2021).

  2. Urbina, F., Lowden, C. T., Culberson, J. C. & Ekins, S.https://doi.org/10.33774/chemrxiv-2021-nlwvs (2021).

  3. Mansouri, K. et al.Environ. Health Perspect.129, 047013 (2021).

    Article  Google Scholar 

  4. Blaschke, T. et al.J. Chem. Inf. Model.60, 5918–5922 (2020).

    Article  Google Scholar 

  5. National Research Council Committee on Toxicology.https://www.ncbi.nlm.nih.gov/books/NBK233724/ (National Academies Press, 1997).

  6. Aroniadou-Anderjaska, V., Apland, J. P., Figueiredo, T. H., De Araujo Furtado, M. & Braga, M. F.Neuropharmacology181, 108298 (2020).

    Article  Google Scholar 

  7. Genheden, S. et al.J. Cheminform.12, 70 (2020).

    Article  Google Scholar 

  8. Coley, C. W. et al.Science365, eaax1566 (2019).

    Article  Google Scholar 

  9. Dix, D. J. et al.Toxicol. Sci.95, 5–12 (2007).

    Article  Google Scholar 

  10. Hutson, M.The New Yorkerhttps://www.newyorker.com/tech/annals-of-technology/who-should-stop-unethical-ai (2021).

  11. Brown, T. B. et al. Preprint atarXivhttps://arxiv.org/abs/2005.14165 (2020).

  12. Prunkl, C. E. A. et al.Nat. Mach. Intell.3, 104–110 (2021).

    Article  Google Scholar 

  13. Organisation for the Prohibition of Chemical Weapons. The Hague Ethical Guidelineshttps://www.opcw.org/hague-ethical-guidelines (2021).

Download references

Acknowledgements

We are grateful to the organizers and participants of the Spiez Convergence conference 2021 for their feedback and questions. C.I. contributed to this article in his personal capacity. The views expressed in this article are those of the authors only and do not necessarily represent the position or opinion of Spiez Laboratory or the Swiss Government. We kindly acknowledge US National Institutes of Health funding under grant R44GM122196-02A1 from the National Institute of General Medical Sciences and 1R43ES031038-01 and 1R43ES033855-01 from the National Institute of Environmental Health Sciences for our machine learning software development and applications. Research reported in this publication was supported by the National Institute of Environmental Health Sciences of the National Institutes of Health under grants R43ES031038 and 1R43ES033855-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author information

Authors and Affiliations

  1. Collaborations Pharmaceuticals, Inc., Raleigh, NC, USA

    Fabio Urbina & Sean Ekins

  2. Department of War Studies and Department of Global Health & Social Medicine, King’s College London, London, UK

    Filippa Lentzos

  3. Spiez Laboratory, Federal Department of Defence, Civil Protection and Sports, Spiez, Switzerland

    Cédric Invernizzi

Authors
  1. Fabio Urbina
  2. Filippa Lentzos
  3. Cédric Invernizzi
  4. Sean Ekins

Corresponding author

Correspondence toSean Ekins.

Ethics declarations

Competing interests

F.U. and S.E. work for Collaborations Pharmaceuticals, Inc. F.L. and C.I. have no conflicts of interest.

Peer review

Peer review information

Nature Machine Intelligence thanks Gisbert Schneider and Carina Prunkl for their contribution to the peer review of this work.

Rights and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Urbina, F., Lentzos, F., Invernizzi, C.et al. Dual use of artificial-intelligence-powered drug discovery.Nat Mach Intell4, 189–191 (2022). https://doi.org/10.1038/s42256-022-00465-9

Download citation

This article is cited by

Access through your institution
Buy or subscribe

Associated content

Nature Outlook

Robotics and artificial intelligence

Advertisement

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for theNature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly.Sign up for Nature Briefing: Translational Research
[8]ページ先頭
©2009-2025 Movatter.jp